At week 52 , anacetrapib reduced mean LDL-C concentration from 33 mmol/L ( SD 08 ) to 21 mmol/L ( 08 ; percentage change 360 % [ 95 % CI -395 to -325 ] compared with an increase with placebo from 34 mmol/L ( 12 ) to 35 mmol/L ( 16 ; percentage change 37 % [ -12 to 86 ] , with a difference in percentage change between anacetrapib and placebo of -397 % ( 95 % CI -457 to -337 ; p < 00001 ) .